Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years o...
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
About this item
Full title
Author / Creator
Burger, Jan A. , Barr, Paul M. , Robak, Tadeusz , Owen, Carolyn , Ghia, Paolo , Tedeschi, Alessandra , Bairey, Osnat , Hillmen, Peter , Coutre, Steven E. , Devereux, Stephen , Grosicki, Sebastian , McCarthy, Helen , Simpson, David , Offner, Fritz , Moreno, Carol , Dai, Sandra , Lal, Indu , Dean, James P. and Kipps, Thomas J.
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (
n
= 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5–0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1–66...
Alternative Titles
Full title
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7214263
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7214263
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-019-0602-x
